Skip to main content
main-content

Gout and crystal arthropathies

Medications

12-05-2020 | Gout | News

ACR guidelines for gout management published

The American College of Rheumatology has issued updated guidelines for the management of gout.

20-04-2020 | Gout | News

Dapansutrile ‘has substantial potential’ for treating gout flares

Findings from a proof-of-concept phase 2a trial provide preliminary evidence to suggest that dapansutrile, an inhibitor of the NLRP3 inflammasome, may be a promising therapeutic option for gout flares.

03-12-2019 | Gout | News

Febuxostat and allopurinol may raise acute kidney injury risk

Febuxostat and allopurinol are associated with an elevated risk for acute kidney injury, according to study results published in Arthritis Research & Therapy.

11-11-2019 | Gout | News

Naproxen recommended over low-dose colchicine for gout flares

Naproxen and low-dose colchicine are similarly effective in the reduction of pain associated with gout flares, but patients receiving colchicine tend to experience more side-effects, show results from the multicenter, open-label CONTACT trial.

21-10-2019 | Gout | News

Achieving target sUA levels ‘should be a principal goal’ in hyperuricemic patients with gout

People with gout and hyperuricemia who achieve guideline-recommended serum uric acid levels below 0.36 mmol/L have lower risks for overall and cardiovascular mortality than those who do not meet this target, researchers report.

14-03-2019 | Gout | News

FDA approves oral colchicine for gout flare prophylaxis

Oral colchicine has been approved by the US FDA for the prevention of flares in people with gout.

22-02-2019 | Gout | News

FDA warns of increased death risk with febuxostat

The US FDA will update the prescribing information for the gout treatment febuxostat to include a boxed warning for death risk.

17-01-2019 | Gout | News

Anakinra may be a ‘viable treatment option’ for gout

Findings from a randomized trial suggest that treatment with the interleukin-1 receptor antagonist anakinra is noninferior to usual care for the treatment of gout flares.

12-12-2018 | Gout | News

Hepatotoxicity reassurance for febuxostat-treated patients with gout and fatty liver disease

Results of an observational study provide preliminary evidence suggesting that patients with gout and fatty liver disease who are treated with febuxostat do not have an elevated risk for hepatotoxicity.

27-11-2018 | Gout | Article

The challenges of approaching and managing gout

Fields TR. Rheum Dis Clin North Am 2019; 45: 145–157. doi: 10.1016/j.rdc.2018.09.009

Highlights from the 2018 ACR/ARHP Annual Meeting

Editorial board members Oliver FitzGerald and Fernando Pérez-Ruiz provide their highlights from the spondyloarthropathy and crystal arthropathy sessions at the 2018 ACR/ARHP Annual Meeting in Chicago, Illinois, USA.

Gout patients may benefit from nurse-led care

Nurse-led care involving patient education and engagement increases the likelihood of achieving target serum urate levels among individuals with gout, findings from a UK randomized controlled trial suggest.

02-11-2018 | Gout | Highlight | News

Gout patients may benefit from nurse-led care

Nurse-led care involving patient education and engagement increases the likelihood of achieving target serum urate levels among individuals with gout, findings from a UK randomized controlled trial suggest.

31-10-2018 | Psoriatic arthritis | ACR/ARHP 2018 | Article

From the Editorial Board: Highlights from the 2018 ACR/ARHP Annual Meeting

Editorial board members Oliver FitzGerald and Fernando Pérez-Ruiz provide their highlights from the spondyloarthropathy and crystal arthropathy sessions at the 2018 ACR/ARHP Annual Meeting in Chicago, Illinois, USA.

Hyperuricemia and chondrocalcinosis: A clinical challenge for diagnosis and treatment

Editorial board member Fernando Pérez-Ruiz presents an interesting presentation of coexistant hyperuricemia and chondrocalcinosis, and outlines the challenges of diagnosis and management of these conditions.

18-10-2018 | Crystal arthropathies | Case study | Article

Hyperuricemia and chondrocalcinosis: A clinical challenge for diagnosis and treatment

Editorial board member Fernando Pérez-Ruiz presents an interesting presentation of coexistant hyperuricemia and chondrocalcinosis, and outlines the challenges of diagnosis and management of these conditions.

Allopurinol does not increase CKD risk in patients with gout

Allopurinol, given at a starting dose of at least 300 mg/day, does not increase the risk for chronic kidney disease stage 3 or higher, and may in fact reduce it, in patients with newly diagnosed gout, study data show.

11-10-2018 | Gout | Highlight | News

Allopurinol does not increase CKD risk in patients with gout

Allopurinol, given at a starting dose of at least 300 mg/day, does not increase the risk for chronic kidney disease stage 3 or higher, and may in fact reduce it, in patients with newly diagnosed gout, study data show.

IL-1 beta inhibition reduces gout attack risk

Administration of canakinumab, an interleukin-1β inhibitor, every 3 months is associated with a significantly reduced risk for gout, without lowering serum uric acid levels, shows a secondary exploratory analysis of the CANTOS trial.

Calcium crystal deposition diseases: Beyond gout

In this review, the main clinical manifestations of calcium pyrophosphate dihydrate and basic calcium phosphate crystal deposition are discussed, along with the biological effects of these crystals, current therapeutic approaches and future directions in therapy [read more].
McCarthy GM, Dunne A. Nat Rev Rheumatol 2018. doi: 10.1038/s41584-018-0078-5

Image Credits